ethyl-α-(1-hydroxycyclohexyl) acetate | 37722-81-9

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: ethyl-α-(1-hydroxycyclohexyl) acetate
• 英文别名: (2-hydroxy-cyclohexyl)-acetic acid ethyl ester；(2-Hydroxy-cyclohexyl)-essigsaeure-aethylester；Ethyl 2-(2-hydroxycyclohexyl)acetate
• CAS: 37722-81-9
• 化学式: C₁₀H₁₈O₃
• 分子量: 186.251
• InChiKey: UJDIXCMHAJFAQL-UHFFFAOYSA-N

物化性质

• 沸点：
  114 °C(Press: 13 Torr)
• 密度：
  1.049±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.4
• 重原子数：
  13
• 可旋转键数：
  4
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.9
• 拓扑面积：
  46.5
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  ethyl-α-(1-hydroxycyclohexyl) acetate 生成 八氢苯并呋喃-2-酮
  参考文献：
  名称：

  PODRAZA, KENNETH F., J. HETEROCYCL. CHEM., 24,(1987) N 1, 293-295

  摘要：

  DOI：
• 作为产物：
  描述：

  2-环己酮乙酸乙酯 在 sodium cyanoborohydride 作用下， 以 四氢呋喃 为溶剂， 生成 ethyl-α-(1-hydroxycyclohexyl) acetate
  参考文献：
  名称：

  Podraza, Kenneth F., Journal of Heterocyclic Chemistry, 1987, vol. 24, p. 293 - 295

  摘要：

  DOI：

文献信息

• PDE9 inhibitors for treating type 2 diabetes,metabolic syndrome, and cardiovascular disease
  申请人：Pfizer Inc.

  公开号：US20040220186A1

  公开（公告）日：2004-11-04

  The invention provides compounds of Formula (I) 1 the stereoisomers and prodrugs thereof, and the pharmaceutically acceptable salts of the compounds, stereoisomers, and prodrugs, wherein A, P, J, x, and R 10 are as defined herein; pharmaceutical compositions thereof; and methods of using the pharmaceutical compositions for the treatment of diseases, including, diabetes, including type 1 and type 2 diabetes, hyperglycemia, dyslipidemia, impaired glucose tolerance, metabolic syndrome, and/or cardiovascular disease.

  该发明提供了公式（I）1的化合物及其立体异构体和前药，以及该化合物、立体异构体和前药的药学上可接受的盐，其中A、P、J、x和R10如本文所定义；其制药组合物；以及使用该制药组合物治疗疾病的方法，包括糖尿病，包括1型和2型糖尿病，高血糖，血脂异常，葡萄糖耐量受损，代谢综合征和/或心血管疾病。
• Reactions of zirconium(IV) isopropoxide with aliphatic and aromatic hydroxy esters. Part I, five-, six, seven- and eight-coordinated zirconium(IV) complexes
  作者：M. Pal、R.N. Kapoor

  DOI：10.1016/s0020-1693(00)91987-x

  日期：1980.1

  The reactions of zirconium(IV) isopropoxide with ethyl-α-(1-hydroxycyclohexyl) acetate (HOC6H10R), ethyl-β-hydroxy-β-phenyl propionate (HOCHPhR) and ethyl-β-hydroxy-β-phenyl butyrate (HOCMePhR), where (R = CH2CO2Et), have been carried out in refluxing benzene in different molar ratios under strictly anhydrous conditions. The dark brown products of the general composition, Zr(OPri)4−n·Ln, (where L =

  异丙醇锆（IV）与乙酸乙酯-α-（1-羟基环己基）乙酸酯（HOC6H10R），乙基-β-羟基-β-苯基丙酸酯（HOCHPhR）和乙基-β-羟基-β-苯基丁酸酯（HOCMePhR）的反应，其中（R = CH2CO2Et），是在严格无水的条件下，以不同摩尔比在回流的苯中进行的。根据元素分析，分子量，红外光谱和红外光谱分析，已分离出具有一般组成的深棕色产物Zr（OPri）4-n·Ln（其中L =羟基酯阴离子； n = 1-4）。质子磁共振波谱研究。
• 239. Synthetical studies in the decalin series. Part I. The preparation of 9-substituted decalins
  作者：George Roger Clemo、John Ormston

  DOI：10.1039/jr9320001778

  日期：——
• MNK INHIBITORS AND METHODS RELATED THERETO
  申请人：eFFECTOR Therapeutics Inc.

  公开号：US20210338673A1

  公开（公告）日：2021-11-04

  The present invention relates to compounds according to Formula (I): or a stereoisomer, tautomer or pharmaceutically acceptable salt thereof, wherein R 1 , R 2 , R 3 , R 4a , R 4b , R 5 , R 6 , R 7 , R 8 , W 1 , W 2 , Y and n are as defined herein. Also described are pharmaceutically acceptable compositions of Formula I compounds as well as methods for utilizing the compounds of Formula I and the pharmaceutically acceptable compositions of Formula I compounds as inhibitors of Mnk as well as therapeutics for the treatment of diseases such as cancer.
• [EN] PDE9 INHIBITORS FOR TREATING TYPE 2 DIABETES, METABOKIC SYNDROME, AND CARDIOVASCULAR DISEASE<br/>[FR] INHIBITEURS DE PDE9 POUR LE TRAITEMENT DU DIABETE DE TYPE 2, DU SYNDROME METABOLIQUE ET DE MALADIES CARDIO-VASCULAIRES
  申请人：PFIZER PROD INC

  公开号：WO2004096811A1

  公开（公告）日：2004-11-11

  The invention provides compounds of Formula (I) the stereoisomers and prod rugs thereof, and the pharmaceutically acceptable salts of the compounds, stereoisomers, and prodrugs, wherein A, P, J, x, and R10 are as defined herein; pharmaceutical compositions thereof; and methods of using the pharmaceutical compositions for the treatment of diseases, including, diabetes, including type 1 and type 2 diabetes, hyperglycemia, dyslipidemia, impaired glucose tolerance, metabolic syndrome, and/or cardiovascular disease.